Cardiovascular comorbidity in COPD: Systematic literature review

Chest

Volumn 144, Issue 4, 2013, Pages 1163-1178

  Müllerova, Hana ^a   Agusti, Alvar ^b   Erqou, Sebhat ^c   Mapel, Douglas W ^d  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF BARCELONA   (Spain)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d LOVELACE CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885109944     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-2847     Document Type: Article

References (51)

1. National Heart, Lung, and Blood Institute. Morbidity and mortality: 2009 chart book on cardiovascular, lung, and blood diseases. 2009.National Heart, Lung, and Blood Institute website. http://www.nhlbi.nih.gov/resources/docs/2009- ChartBook.pdf. Accessed January 5, 2012.
2. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006; 28 (6): 1245-1257.
3. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA; TORCH Clinical Endpoint Committee. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax. 2007; 62 (5): 411-415.
4. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006; 16 (1): 63-70.
5. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest. 2005; 128 (4): 2640-2646.
6. Macchia A, Monte S, Romero M, D'Ettorre A, Tognoni G. The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure. Eur J Heart Fail. 2007; 9 (9): 942-948.
7. Sidney S, Sorel M, Quesenberry CP Jr, DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest. 2005; 128 (4): 2068-2075.
8. Agustí A, Edwards LD, Rennard SI, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE. 2012; 7 (5): e37483.
9. Barr RG, Bluemke DA, Ahmed FS, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010; 362 (3): 217-227.
10. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011; 342: d2549.
11. Hawkins NM, Petrie MC, Macdonald MR, et al. Heart failure and chronic obstructive pulmonary disease the quandary of beta-blockers and beta-agonists. J Am Coll Cardiol. 2011; 57 (21): 2127-2138.
12. Allen NB, Holford TR, Bracken MB, et al. Geographic variation in one-year recurrent ischemic stroke rates for elderly Medicare beneficiaries in the USA. Neuroepidemiology. 2010; 34 (2): 123-129.
13. Chen Y, Li Q, Johansen H. Age and sex variations in hospital readmissions for COPD associated with overall and cardiac comorbidity. Int J Tuberc Lung Dis. 2009; 13 (3): 394-399.
14. Cordero A, Bertomeu-Martínez V, Mazón P, et al. Factors associated with uncontrolled hypertension in patients with and without cardiovascular disease [in Spanish]. Rev Esp Cardiol. 2011; 64 (7): 587-593.
15. de Lucas-Ramos P, Izquierdo-Alonso JL, Rodríguez-González Moro JM, et al. Cardiovascular risk factors in chronic obstructive pulmonary disease: results of the ARCE study [in Spanish]. Arch Bronconeumol. 2008; 44 (5): 233-238.
16. Dziewierz A, Siudak Z, Rakowski T, Jakała J, Dubiel JS, Dudek D. Prognostic significance of new onset atrial fibrillation in acute coronary syndrome patients treated conservatively. Cardiol J. 2010; 17 (1): 57-64.
17. Enriquez JR, Parikh SV, Selzer F, et al. Increased adverse events after percutaneous coronary intervention in patients with COPD: insights from the National Heart, Lung, and Blood Institute dynamic registry. Chest. 2011; 140(3): 604-610.
18. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010; 65 (11): 956-962.
19. Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis. 2009; 4: 337-349.
20. García Rodríguez LA, Wallander MA, Tolosa LB, Johansson S. Chronic obstructive pulmonary disease in UK primary care: incidence and risk factors. COPD. 2009; 6 (5): 369-379.
21. García Rodríguez LA, Wallander MA, Martín-Merino E, Johansson S. Heart failure, myocardial infarction, lung cancer and death in COPD patients: a UK primary care study. Respir Med. 2010; 104 (11): 1691-1699.
22. Izquierdo JL, Martínez A, Guzmán E, de Lucas P, Rodríguez JM. Lack of association of ischemic heart disease with COPD when taking into account classical cardiovascular risk factors. Int J Chron Obstruct Pulmon Dis. 2010; 5: 387-394.
23. Johnston AK, Mannino DM, Hagan GW, Davis KJ, Kiri VA. Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort. Thorax. 2008; 63 (7): 599-605.
24. Konecny T, Somers K, Orban M, et al. Interactions between COPD and outcomes after percutaneous coronary intervention. Chest. 2010; 138 (3): 621-627.
25. Lange P, Mogelvang R, Marott JL, Vestbo J, Jensen JS. Cardiovascular morbidity in COPD: A study of the general population. COPD. 2010; 7 (1): 5-10.
26. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008; 32 (4): 962-969.
27. Mapel DW, Dedrick D, Davis K. Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991-1999. COPD. 2005; 2 (1): 35-41.
28. Methvin JN, Mannino DM, Casey BR. COPD prevalence in southeastern Kentucky: the burden of lung disease study. Chest. 2009; 135 (1): 102-107.
29. Sode BF, Dahl M, Nordestgaard BG. Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a Danish nationwide study of 7.4 million individuals. Eur Heart J. 2011; 32 (19): 2365-2375.
30. Staszewsky L, Wong M, Masson S, et al; Valsartan Heart Failure Trial Investigators. Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial. J Card Fail. 2007; 13 (10): 797-804.
31. Schneider C, Bothner U, Jick SS, Meier CR. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol. 2010; 25 (4): 253-260.
32. Tseng CH. Clinical features of heart failure hospitalization in younger and elderly patients in Taiwan. Eur J Clin Invest. 2011; 41 (6): 597-604.
33. Wang YC, Lin JM, Li CY, Lee LT, Guo YL, Sung FC. Prevalence and risks of chronic airway obstruction: a population cohort study in Taiwan. Chest. 2007; 131 (3): 705-710.
34. Agustí AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003; 21 (2): 347-360.
35. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004; 59 (7): 574-580.
36. MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005; 2 (1): 50-60.
37. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 175 (12): 1259-1265.
38. Maclay JD, McAllister DA, Mills NL, et al. Vascular dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009; 180 (6): 513-520.
39. Schols AM, Fredrix EW, Soeters PB, Westerterp KR, Wouters EF. Resting energy expenditure in patients with chronic obstructive pulmonary disease. Am J Clin Nutr. 1991; 54 (6): 983-987.
40. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. Am J Respir Crit Care Med. 2007; 175 (5): 458-463.
41. Naeije R, Barberà JA. Pulmonary hypertension associated with COPD. Crit Care. 2001; 5 (6): 286-289.
42. Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J. 2003; 21 (6): 1012-1016.
43. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011.Global strategy for the diagnosis, management and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease website. http://www.goldcopd. org/guidelinesglobal- strategy-for-diagnosis-management.html/. Accessed August, 2012.
44. Soriano JB, Rigo F, Guerrero D, et al. High prevalence of undiagnosed airflow limitation in patients with cardiovascular disease. Chest. 2010; 137 (2): 333-340.
45. Agarwal SK, Heiss G, Barr RG, et al. Airflow obstruction, lung function, and risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study. Eur J Heart Fail. 2012; 14 (4): 414-422.
46. Barac A, Wang H, Shara NM, et al. Markers of inflammation, metabolic risk factors, and incident heart failure in American Indians: the Strong Heart Study. J Clin Hypertens (Greenwich). 2012; 14 (1): 13-19.
47. Bahrami H, Bluemke DA, Kronmal R, et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol. 2008; 51 (18): 1775-1783.
48. Valvi D, Mannino DM, Müllerova H, Tal-Singer R. Fibrinogen, chronic obstructive pulmonary disease (COPD) and outcomes in two United States cohorts. Int J Chron Obstruct Pulmon Dis. 2012; 7: 173-182.
49. Peña JM, MacFadyen J, Glynn RJ, Ridker PM. Highsensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Eur Heart J. 2012; 33 (4): 531-537.
50. Emberson J, Bennett D, Link E, et al; Heart Protection Study Collaborative Group. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet. 2011; 377 (9764): 469-476.
51. Shepard JW Jr, Garrison MW, Grither DA, Evans R, Schweitzer PK. Relationship of ventricular ectopy to nocturnal oxygen desaturation in patients with chronic obstructive pulmonary disease. Am J Med. 1985; 78 (1): 28-34.